Granules India receives ANDA approval for Gabapentin Tablets

Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults

Granules India inaugurates packaging facility in Virginia

The facility is over 79,000 square feet and is equipped with packaging lines

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.

Granules India’s Gagillapur facility completes USFDA inspection

The company will respond to these observations within the stipulated time period.

Granules India appoints Mukesh Surana as CFO

Surana is a chartered accountant with an all-India rank.

Granules India CFO Sandip Neogi resigns

The company is in the process of appointing a new CFO.

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track

Granules India inaugurated water tank at Bonthapally village

The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER

Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).